Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
673 Results for "
K-Ras
" in MedChemExpress (MCE) Product Catalog:
Products (673)
673 Results for "K-Ras" in MCE Product Catalog:
Cat. No.: HY-146475
CAS No.: 2230873-65-9
KRAS inhibitor-17 (compound 3-9) is a potent KRAS G12C inhibitor with an IC50 of 3.37 µM. KRAS inhibitor-17 shows p-ERK inhibition activities with IC50s of 9.25, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-17 has the potential for the research of pancreatic, colorectal, and lung cancers .
Cat. No.: HY-P704771
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KRas; KRas-Enoph1 Fusion Protein; Prev. KRas2; PR310 C-K-Ras Oncogene; GTPase KRas; Small Monomeric GTPase; K-Ras4B; C-Kirsten-Ras Protein; KRas1; Proto-Oncogene GTPase; V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog; KRas-ENOPH Fusion; Kirsten Ra
Species:
Human
Source:
E. coli
Cat. No.: HY-L260
82 compounds
KRAS (Kirsten Rat Sarcoma Viral Oncogene Homolog) is one of the most important oncogenic driver genes in oncology, with high mutation frequencies in pancreatic cancer, non‑small cell lung cancer, and colorectal cancer. For a long time, KRAS was considered "undruggable" due to the lack of suitable small‑molecule binding pockets on its protein surface. In recent years, with the discovery of the switch‑II pocket and the successful approval of KRAS G12C inhibitors, KRAS‑targeted research has achieved groundbreaking progress, which has also spurred a wave of development targeting non‑G12C mutants such as G12D and G12V, as well as upstream and downstream regulatory factors including SOS1 and SHP2.
MCE KRAS Targeted Compound Library contains 82 small‑molecule compounds targeting the KRAS, serving as high‑quality research tools for mechanistic studies of KRAS‑mutant tumors, combination therapy development, resistance mechanism exploration, and high‑throughput drug screening, thereby providing robust support for KRAS‑targeted drug discovery.
Cat. No.: HY-182749
KRAS-IN-58 is a KRAS inhibitor with a IC50 of 0.223 μM against KRAS G12D. KRAS-IN-58 binds to KRAS G12C and KRAS G12D proteins, and reduces the levels of phosphorylated Raf1, AKT and ERK in pancreatic cancer cells. KRAS-IN-58 can be used for the research of pancreatic cancer .
Cat. No.: HY-182411
CAS No.: 2375482-34-9
KRAS-IN-56 (Compound 18) is a KRAS inhibitor with an EC50 of 33 μM. KRAS-IN-56 inhibits the interaction between GTP-KRAS and SOS1. KRAS-IN-56 induces a decrease in p-ERK levels. KRAS-IN-56 can be used in research related to lung cancer .
Cat. No.: HY-187519
KRAS-IN-61 is an orally effective pan-KRAS inhibitor that potently inhibits SOS1-mediated KRAS nucleotide exchange (IC50 <10 nM for KRAS G12D/G12V/G12C/WT). KRAS-IN-61 inhibits pERK signaling and cell proliferation in KRAS-mutant tumor cells. KRAS-IN-61 can inhibit tumor growth in vivo. KRAS-IN-61 can be used in studies of KRAS mutation-related cancers, such as colorectal cancer .
Cat. No.: HY-181704
CAS No.: 3084918-70-4
KRAS-IN-54 is a macrocyclic KRAS inhibitor. KRAS-IN-54 exhibits activity against cell viability and pERK inhibition in cells with KRAS G12D and KRAS G13D mutations. KRAS-IN-54 can be used in the research of KRAS-mutant cancers, including pancreatic adenocarcinoma, colorectal cancer, non-small cell lung cancer, esophageal cancer, gallbladder cancer, melanoma, ovarian cancer and endometrial cancer .
Cat. No.: HY-181883
KRAS-IN-55 is a pan-KRAS inhibitor with IC50 values of 4.3, 9.6 and 1.6 nM against KRAS G12C, KRAS G12D and KRAS G12V, respectively. KRAS-IN-55 induces the formation of a new binding pocket on KRAS, thereby forming a high-affinity ternary complex with cyclophilin A (CYPA), inhibiting the interactions of KRAS with downstream effectors RAF and PI3K, and blocking oncogenic MAPK and PI3K signaling pathways. KRAS-IN-55 is applicable to cancer research such as colorectal cancer and non-small cell lung cancer .
Cat. No.: HY-189278
KRAS-IN-64 is a KRAS inhibitor that inhibits KRAS translation by binding to and stabilizing the G-quadruplex in the 5'-UTR of KRAS mRNA, exhibits antiproliferative activity in KRAS-mutant cancer cells, and induces cell cycle arrest, non-apoptotic cell death, and PARP cleavage-mediated apoptosis (apoptosis). KRAS-IN-64 can be used for research on pancreatic cancer .
Cat. No.: HY-187520
CAS No.: 3137385-11-3
KRAS-IN-62 is an orally effective pan-KRAS inhibitor that potently inhibits SOS1-mediated KRAS nucleotide exchange (IC50 < 10 nM for KRAS G12D/G12V/G12C/WT). KRAS-IN-62 inhibits pERK signaling and cell proliferation in KRAS-mutant tumor cells (pERK IC90 = 0.51 nM in GP2D cells). KRAS-IN-62 inhibits tumor growth in vivo, with plasma concentrations exceeding IC50 for ~20 h after oral administration in beagle dogs. KRAS-IN-62 can be used in studies of KRAS mutation-related cancers, such as colorectal cancer .
Cat. No.: HY-186024
CAS No.: 3076211-50-9
KRAS-IN-51 (Compound 597a) is a KRas G12V inhibitor, with its IC50 for KRas G12V being 2.9 nM; KD values are 17 (at 20°C) and 68 (at 37°C) nM. KRAS-IN-51 inhibits the phosphorylation of pERK. KRAS-IN-51 has anti-proliferative activity against SW620 and MIAPaCa-2. KRAS-IN-51 can be used for research on colorectal cancer and pancreatic cancer .
Cat. No.: HY-P70233
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: KRas; KRas-Enoph1 Fusion Protein; Prev. KRas2; PR310 C-K-Ras Oncogene; GTPase KRas; Small Monomeric GTPase; K-Ras4B; C-Kirsten-Ras Protein; KRas1; Proto-Oncogene GTPase; V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog; KRas-ENOPH Fusion; Kirsten Ra
Species:
Human
Source:
E. coli
Cat. No.: HY-P70233A
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: KRas; KRas-Enoph1 Fusion Protein; Prev. KRas2; PR310 C-K-Ras Oncogene; GTPase KRas; Small Monomeric GTPase; K-Ras4B; C-Kirsten-Ras Protein; KRas1; Proto-Oncogene GTPase; V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog; KRas-ENOPH Fusion; Kirsten Ra
Species:
Human
Source:
E. coli
Cat. No.: HY-P704746
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: KRas; KRas-Enoph1 Fusion Protein; Prev. KRas2; PR310 C-K-Ras Oncogene; GTPase KRas; Small Monomeric GTPase; K-Ras4B; C-Kirsten-Ras Protein; KRas1; Proto-Oncogene GTPase; V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog; KRas-ENOPH Fusion; Kirsten Ra
Species:
Human
Source:
sf9 insect cells
Cat. No.: HY-P86935
Synonyms: c Ki Ras2 antibody; c Kirsten Ras protein antibody; c-K-Ras antibody; c-Ki-Ras antibody; Cellular c Ki Ras2 proto oncogene antibody; Cellular transforming proto oncogene antibody; CFC2 antibody; cK Ras antibody; GTPase KRas antibody; K Ras p21 protein antibody; c Ki Ras2 antibody; c Kirsten Ras protein antibody; c-K-Ras antibody; c-Ki-Ras antibody; Cellular c Ki Ras2 proto oncogene antibody; Cellular transforming proto oncogene antibody; CFC2 antibody; cK Ras antibody; GTPase KRas antibody; K Ras p21 protein antibody; K Ras2A antibody; K Ras2B antibody; K Ras4A antibody; K Ras4B antibody; K-Ras 2 antibody; KI Ras antibody; Ki-Ras antibody; KIRSTEN MURINE SARCOMA VIRUS 2 antibody; Kirsten rat sarcoma 2 viral (v Ki Ras2) oncogene homolog antibody; Kirsten rat sarcoma viral oncogene homolog antibody; KRas antibody; KRas proto oncogene, GTPase antibody; KRas1 antibody; KRas2 antibody; N-terminally processed antibody; NS antibody; NS3 antibody; Oncogene KRas2 antibody; p21Ras antibody; PR310 c K Ras oncogene antibody; PR310 cK Ras oncogene antibody; RALD antibody; RasK_HUMAN antibody; RasK2 antibody; Transforming protein p21 antibody; v Ki Ras2 Kirsten rat sarcoma 2 viral oncogene homolog antibody; v Ki Ras2 Kirsten rat sarcoma viral oncogene homolog antibody;
Cat. No.: HY-189223
KRAS ligand 6 (Compound 37) is a KRAS ligand. KRAS ligand 6 can be used as a Ligand for Target Protein for PROTAC to synthesize KRAS PROTAC degraders, such as RP04340 (HY-189222). KRAS ligand 6 can be used for research on KRAS-driven cancers, including pancreatic ductal adenocarcinoma, colorectal cancer, and lung adenocarcinoma .
Cat. No.: HY-179300
CAS No.: 3074833-86-3
KRAS-IN-48 free base (Compound 1-01) is a mutant KRAS inhibitor, with Kd values of 2.58 nM and 5.49 μM for KRAS G12D and KRAS G12V, respectively. KRAS-IN-48 free base affects pERK expression in cells harboring KRAS G12D and KRAS G12V mutations, with IC50 values of 1.1 μM and 1.51 μM, respectively. KRAS-IN-48 free base can be used in the research of cancer .
Cat. No.: HY-P7804
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: KRas; KRas-Enoph1 Fusion Protein; Prev. KRas2; PR310 C-K-Ras Oncogene; GTPase KRas; Small Monomeric GTPase; K-Ras4B; C-Kirsten-Ras Protein; KRas1; Proto-Oncogene GTPase; V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog; KRas-ENOPH Fusion; Kirsten Ra
Species:
Human
Source:
E. coli
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
